AHOD1331: Cost Effectivess Analysis (CEA) of Brentuximab Vedotin in Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Grants and Contracts Details

Description

HUMAN CLINICAL TRIAL - CONFIDENTIAL COG Protocol AHOD1331 entitled, “A Randomized Phase III Study of Brentuximab vedotin (IND#117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents” SUBCONTRACTE shall carry out the clinical trial research sub-study, “Cost Effectiveness Analysis (CEA) of Brentuximab Vedotin in Newly Diagnosed High-Risk Classical Hodgkin lymphoma (cHL) in Children and Adolescents,” set forth in the research protocol COG Protocol AHOD1331 entitled, “A Randomized Phase III Study of Brentuximab vedotin (IND#117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents”
StatusActive
Effective start/end date5/15/2110/13/24

Funding

  • Public Health Institute: $2.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.